Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chaihu Huaji Fang is a Traditional Chinese Medicine (TCM) formula derived from the integration of Xiao Chaihu decoction and Hua Ji pill. Traditionally, it is used to soothe the liver, invigorate the spleen, eliminate pathogenic factors, and move qi to dissipate blood stasis. Modern research indicates its potential in alleviating postembolization syndrome (PES) following Transcatheter Arterial Chemoembolization (TACE) for unresectable hepatocellular carcinoma, demonstrating improvements in symptoms like fever, nausea, vomiting, poor appetite, and leukocytopenia, and enhancing 3-year overall survival. Its primary ingredient, Chaihu (Bupleurum), and its active components, saikosaponins, have been shown to possess immunomodulatory, antiviral, antipyretic, hepatoprotective, anticancer, sedative, and analgesic properties, partly through mechanisms such as autophagy induction.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Chaihu Huaji Fang.